Loading..

Gelesis Holdings, Inc. (GLS) Report Analysis

Corporate Events

Neutral

Gelesis Holdings, Inc. Announces Additional $15...

2022-06-21 10:30:00

Gelesis Holdings, Inc. announced that Ro has placed a $15 million pre-paid order for the company’s commercial product for weight management, P...

Positive

Gelesis Holdings, Inc.(NYSE:GLS) added to S&P G...

2022-06-20 00:00:00

Gelesis Holdings, Inc.(NYSE:GLS) added to S&P Global BMI Index

Neutral

Gelesis Holdings, Inc. Presents at 7th Microbio...

2022-06-15 18:00:00

Gelesis Holdings, Inc. Presents at 7th Microbiome Movement Drug Development Summit, Jun-22-2022 03:30 PM. Venue: Westin Boston Seaport Distric...

Neutral

Hanson Wade Limited, 7th Microbiome Movement Dr...

2022-06-15 11:41:00

Hanson Wade Limited, 7th Microbiome Movement Drug Development Summit, Jun 21, 2022 through Jun 24, 2022. Venue: Westin Boston Seaport District...

Neutral

Gelesis Holdings, Inc. has closed its Shelf Reg...

2022-06-07 00:00:00

Gelesis Holdings, Inc. has closed its Shelf Registration dated February 11, 2022 in the amount of $508.696819 million. Security Name: Commo...

Positive

Microbiota Transplantation Demonstrates How Gut...

2022-06-04 15:00:00

Gelesis Holdings, Inc. presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a microbiota tra...

Negative

Gelesis Holdings, Inc. Auditor Raises 'Going Co...

2022-05-24 00:00:00

Gelesis Holdings, Inc. filed its S-1/A on May 24, 2022 for the period ending Dec 31, 2021. In this report its auditor, KPMG LLP - Klynveld Pea...

Neutral

Gelesis Holdings, Inc. Presents at UBS Global H...

2022-05-18 20:05:00

Gelesis Holdings, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 08:30 AM. Venue: Lotte New York Palace, New York City, New Yo...

Neutral

Gelesis Holdings, Inc. Presents at Loop Capital...

2022-05-18 20:05:00

Gelesis Holdings, Inc. Presents at Loop Capital Markets Technology, Media and Telecom Conference, Jun-01-2022 . Venue: Lotte New York Palace, ...

Neutral

Gelesis Holdings, Inc. Provides Revenue Guidanc...

2022-05-12 20:30:00

Gelesis Holdings, Inc. provided revenue guidance for the year 2022. For the year, the company expects net product revenues of $58 million, whi...

Negative

Gelesis Holdings, Inc. Announces Auditor Changes

2022-05-10 20:40:00

On May 9, 2022, the audit committee of the Board of Gelesis Holdings, Inc. approved a resolution appointing KPMG LLP (KPMG) as company's indep...

Neutral

Gelesis Holdings, Inc. to Report Q1, 2022 Resul...

2022-05-09 10:00:00

Gelesis Holdings, Inc. announced that they will report Q1, 2022 results After-Market on May 12, 2022

Neutral

Gelesis Holdings, Inc., Q1 2022 Earnings Call, ...

2022-05-09 10:00:00

Gelesis Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022

Neutral

Gelesis Holdings, Inc. has filed a Shelf Regist...

2022-05-06 00:00:00

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $117.289387 million. Security Name: Common Stock Securities Offered...

Positive

Gelesis Announces Clinical Data Demonstrating W...

2022-05-04 10:35:00

Gelesis presented results from the LIGHT-UP clinical trial for adults with overweight or obesity who have prediabetes or type 2 diabetes and w...

Negative

Gelesis Holdings, Inc. announced delayed annual...

2022-04-01 00:00:00

On 04/01/2022, Gelesis Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Neutral

Gelesis Holdings, Inc. Provides Revenue Guidanc...

2022-03-24 20:00:00

Gelesis Holdings, Inc. provides revenue guidance for the full year 2022. The company estimates product revenue, net, of about $58 million in 2022.

Neutral

Loop Capital Markets LLC, Loop Capital Markets ...

2022-03-17 15:04:00

Loop Capital Markets LLC, Loop Capital Markets Technology, Media and Telecom Conference, Jun 01, 2022 through Jun 02, 2022. Venue: Lotte New Y...

Neutral

UBS Investment Bank, UBS Global Healthcare Conf...

2022-03-03 04:07:00

UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022. Venue: Lotte New York Palace, New York City, New Yor...

Neutral

Gelesis Holdings, Inc. has filed a Shelf Regist...

2022-02-11 00:00:00

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $434.291987 million. Security Name: Common Stock Securities Offered...

Neutral

Gelesis Holdings, Inc. Provides Revenue Guidanc...

2022-01-31 11:50:00

Gelesis Holdings, Inc. provided revenue guidance for the year 2022. The company currently anticipates that its 2022 revenue will be approximat...

Negative

Gelesis, Inc. Appoints Joy Bauer as Chief Nutri...

2021-12-01 12:10:00

Gelesis, Inc. announced the appointment of Joy Bauer, MS, RDN, CDN, as Chief Nutrition Officer.

Positive

Gelesis, Inc. Announces FDA-Cleared Weight Mana...

2021-12-01 12:10:00

Gelesis, Inc. announced that Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults ...

Neutral

Gelesis, Inc. Receives $30 Million Plenity Orde...

2021-11-18 12:10:00

Gelesis, Inc. announced that Ro has placed a $30 million fully paid pre-order for the company's first commercial product for weight management...

Negative

Gelesis, Inc. Auditor Raises 'Going Concern' Doubt

2021-11-09 00:00:00

Gelesis, Inc. filed its Annual on Nov 09, 2021 for the period ending Dec 31, 2020. In this report its auditor, KPMG LLP - Klynveld Peat Marwic...

Positive

Capstar Special Purpose Acquisition Corp., Gele...

2021-07-19 11:00:00

To discuss business combination agreement between Gelesis, Inc. and Capstar Special Purpose Acquisition Corp.

Positive

Gelesis, Inc. announced that it expects to rece...

2021-07-19 00:00:00

Gelesis, Inc. announced that it has entered into subscription agreements with certain investors for private placement of up to 10,000,000 clas...

Positive

Gelesis, Inc. entered letter of intent to acqui...

2021-07-19 00:00:00

Gelesis, Inc. entered letter of intent to acquire Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders for $1.1 ...

Neutral

Gelesis Holdings, Inc. Announces Additional $15 Million Pre-Order for Plenity, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million

2022-06-21 10:30:00

Gelesis Holdings, Inc. announced that Ro has placed a $15 million pre-paid order for the company’s commercial product for weight management, Plenity®. This is in addition to previous Plenity pre-orders from Ro totaling $40 million. Gelesis launched the first wave of its national broad awareness media campaign for Plenity on January 31, 2022, which corresponded with record high levels of web traffic and prescription requests. Since the broad consumer launch, Plenity has become one of the most sought-after offerings on Ro’s platform. After a consultation with a licensed healthcare provider, if they qualify, individuals can be approved for a prescription within 24 hours. The treatment is then shipped directly to their home and arrives within 2 days, at $98 for a 28-day supply. Following the launch of the campaign, the number of individuals seeking a new prescription increased 140% during the first quarter to reach record highs. The company reported $7.5 million in net product revenue in the first quarter of 2022, a 142% increase over the first quarter 2021. Gelesis has also reported growth in the more traditional healthcare provider (HCP) channel following the launch of the campaign and the company expects consumer demand to continue to drive uptake. Notably 40-50% of these HCP prescriptions were requested by the consumer (the company’s baseline before the media campaign began was 25%). Plenity has the large addressable market of any prescription weight management approach, and 150 million American adults could qualify for treatment, including the tens of millions of Americans with a BMI between 25 and 30 who generally do not qualify for other prescription weight loss treatments. About 70% of Plenity members had never tried a prescription weight management product before, indicating Plenity is bringing new people into the category of prescription weight management products.

Positive

Gelesis Holdings, Inc.(NYSE:GLS) added to S&P Global BMI Index

2022-06-20 00:00:00

Gelesis Holdings, Inc.(NYSE:GLS) added to S&P Global BMI Index

Neutral

Gelesis Holdings, Inc. Presents at 7th Microbiome Movement Drug Development Summit, Jun-22-2022 03:30 PM

2022-06-15 18:00:00

Gelesis Holdings, Inc. Presents at 7th Microbiome Movement Drug Development Summit, Jun-22-2022 03:30 PM. Venue: Westin Boston Seaport District, 425 Summer St., Boston, Massachusetts, United States. Speakers: Bryan Jones, Senior Director.

Neutral

Hanson Wade Limited, 7th Microbiome Movement Drug Development Summit, Jun 21, 2022 through Jun 24, 2022

2022-06-15 11:41:00

Hanson Wade Limited, 7th Microbiome Movement Drug Development Summit, Jun 21, 2022 through Jun 24, 2022. Venue: Westin Boston Seaport District, 425 Summer St., Boston, Massachusetts, United States.

Neutral

Gelesis Holdings, Inc. has closed its Shelf Registration dated February 11, 2022 in the amount of $508.696819 million.

2022-06-07 00:00:00

Gelesis Holdings, Inc. has closed its Shelf Registration dated February 11, 2022 in the amount of $508.696819 million. Security Name: Common Stock Securities Offered: 132,857,109 Security Name: Warrants Securities Offered: 24,333,365

Positive

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel

2022-06-04 15:00:00

Gelesis Holdings, Inc. presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a microbiota transplant from another group of mice, treated with one of the company’s proprietary hydrogels. These metabolic benefits occurred while both groups of mice, the donors of the microbiota transplant and the recipient mice, were on a high fat, high carbohydrate diet typically causing rapid weight gain, obesity, and diabetes. The findings were presented on June 4, 2022 at the American Diabetes Association’s annual conference.Gelesis’ superabsorbent hydrogels are inspired by the composition (cellulose structures holding water) and mechanical properties (elasticity or firmness) of ingested raw vegetables. They are taken by capsules with water before a meal to create a much larger volume of small, non-aggregating hydrogel pieces that act locally in the digestive system without adding any additional calories. One of the hydrogels is commercially available as Plenity® to aid in weight management; others that utilize the same platform technology are in clinical and preclinical studies. In April, Gelesis presented preclinical data at the World of Microbiome conference suggesting that adding superabsorbent hydrogel (Gel-B, an investigational candidate) to a high-fat “western-like” diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain. The study showed a striking effect on gut microbiota composition with enrichment of several key bacteria such as Akkermansia muciniphila, a bacterial species associated with gut health and weight loss. Importantly, an addible fiber (a modified cellulose), used as a positive control, did not support the growth of these species. This same type of modified cellulose is used to create Gelesis’ proprietary hydrogels. The difference in bacterial growth between the linear fiber and the 3-dimensional hydrogel suggests that the effects of the hydrogel on the microbiota are mainly mechanical (i.e. elastic response or firmness). In previous studies, administration of one of these hydrogels, in addition to a high-fat diet, blunted weight gain, reversed gut atrophy, improved metabolic parameters, and restored gut barrier. This new study aimed to investigate whether transferring the microbiota from Gel B-treated mice into the gut of mice fed a high fat, high carbohydrate, high cholesterol (HFHCC) diet for 10 weeks could alleviate the detrimental effects of their diet.The study used intestinal microbiota transfer (IMT) to investigate the functional role of the gut microbiota to explain the metabolic effects associated with Gel-B treatment. Metabolic disease was induced in two cohorts of mice (“Donors” and “Recipients”) via consumption of a high fat, high cholesterol, high carbohydrate diet for 10 weeks. Donors either continued HFHCC or were treated with HFHCC plus Gel-B for 6 additional weeks. Fecal samples were processed from Donors every other day during weeks 2-6 of treatment. Recipients received either intestinal microbiota transfer from Gel-B-treated or untreated Donors. Recipients receiving IMT from untreated Donors continued to gain weight, while Recipients receiving IMT from Gel-B treated Donors lost weight, despite the continued consumption of HFHCC. Treating the recipients with intestinal microbiota of Gel B treated donors also resulted in improvement in glycemic control.

Negative

Gelesis Holdings, Inc. Auditor Raises 'Going Concern' Doubt

2022-05-24 00:00:00

Gelesis Holdings, Inc. filed its S-1/A on May 24, 2022 for the period ending Dec 31, 2021. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Neutral

Gelesis Holdings, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 08:30 AM

2022-05-18 20:05:00

Gelesis Holdings, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 08:30 AM. Venue: Lotte New York Palace, New York City, New York, United States. Speakers: David Pass, COO & Chief Commercial Officer, Elliot Maltz, CFO & Treasurer, Yishai Zohar, Founder, President, CEO & Director.

Neutral

Gelesis Holdings, Inc. Presents at Loop Capital Markets Technology, Media and Telecom Conference, Jun-01-2022

2022-05-18 20:05:00

Gelesis Holdings, Inc. Presents at Loop Capital Markets Technology, Media and Telecom Conference, Jun-01-2022 . Venue: Lotte New York Palace, New York City, New York, United States.

Neutral

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

2022-05-12 20:30:00

Gelesis Holdings, Inc. provided revenue guidance for the year 2022. For the year, the company expects net product revenues of $58 million, which reflects approximately a 400% increase over 2021.

Negative

Gelesis Holdings, Inc. Announces Auditor Changes

2022-05-10 20:40:00

On May 9, 2022, the audit committee of the Board of Gelesis Holdings, Inc. approved a resolution appointing KPMG LLP (KPMG) as company's independent registered public accounting firm to audit consolidated financial statements for the fiscal year ending December 31, 2022. KPMG served as the independent registered public accounting firm of Legacy Gelesis prior to the Business Combination. Accordingly, Marcum LLP (Marcum), CPSR’s independent registered public accounting firm prior to the Business Combination, was informed on May 9, 2022 that it would be replaced by KPMG as Gelesis' independent registered public accounting firm.

Neutral

Gelesis Holdings, Inc. to Report Q1, 2022 Results on May 12, 2022

2022-05-09 10:00:00

Gelesis Holdings, Inc. announced that they will report Q1, 2022 results After-Market on May 12, 2022

Neutral

Gelesis Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022

2022-05-09 10:00:00

Gelesis Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022

Neutral

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $117.289387 million.

2022-05-06 00:00:00

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $117.289387 million. Security Name: Common Stock Securities Offered: 22,997,919 Transaction Features: ESOP Related Offering

Positive

Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

2022-05-04 10:35:00

Gelesis presented results from the LIGHT-UP clinical trial for adults with overweight or obesity who have prediabetes or type 2 diabetes and were treated with either GS200 or placebo. Approximately 6 out of 10 adults treated with GS200 achieved clinically meaningful response to treatment (achieving at least 5% body weight loss), losing on average 11% of their body weight (~23 pounds) and an average reduction of 5.5 inches off their waist circumference. Approximately 1 out of 3 GS200-treated adults were “super responders,” losing at least 10% of their body weight and on average losing 13% (~30 pounds), or 7 inches off their waist circumference. The overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the incidence of AEs in the placebo group. The detailed findings were presented at three poster presentations at the European Congress on Obesity 2022. Anti-obesity medications are prescribed in less than 2% of people with overweight or obesity in the US mainly due to concerns about the safety or tolerability of existing medications. There is a need for orally administered treatments that can induce clinically meaningful weight loss, with no significant increased safety risk, especially in people with type 2 diabetes or prediabetes since they typically face increased challenges losing weight and have higher risk of developing serious comorbidities. GS200 is an orally administered superabsorbent hydrogel taken by capsule with water 10 minutes before lunch and dinner and is designed to act mechanically in the gastrointestinal tract in order to induce satiety in patients with prediabetes and type 2 diabetes. Participants in LIGHT-UP were also instructed to follow a modestly reduced calorie diet along with moderate-intensity physical activity. In the GS200 group there was clear and early separation between responders and non-responders to treatment, and response to therapy could be predicted as early as 6 weeks of treatment.

Negative

Gelesis Holdings, Inc. announced delayed annual 10-K filing

2022-04-01 00:00:00

On 04/01/2022, Gelesis Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Neutral

Gelesis Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

2022-03-24 20:00:00

Gelesis Holdings, Inc. provides revenue guidance for the full year 2022. The company estimates product revenue, net, of about $58 million in 2022.

Neutral

Loop Capital Markets LLC, Loop Capital Markets Technology, Media and Telecom Conference, Jun 01, 2022 through Jun 02, 2022

2022-03-17 15:04:00

Loop Capital Markets LLC, Loop Capital Markets Technology, Media and Telecom Conference, Jun 01, 2022 through Jun 02, 2022. Venue: Lotte New York Palace, New York City, New York, United States.

Neutral

UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022

2022-03-03 04:07:00

UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022. Venue: Lotte New York Palace, New York City, New York, United States.

Neutral

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $434.291987 million.

2022-02-11 00:00:00

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $434.291987 million. Security Name: Common Stock Securities Offered: 132,938,108 Security Name: Warrants Securities Offered: 24,509,491

Neutral

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

2022-01-31 11:50:00

Gelesis Holdings, Inc. provided revenue guidance for the year 2022. The company currently anticipates that its 2022 revenue will be approximately $58 million in its first year of a full launch.

Negative

Gelesis, Inc. Appoints Joy Bauer as Chief Nutrition Officer

2021-12-01 12:10:00

Gelesis, Inc. announced the appointment of Joy Bauer, MS, RDN, CDN, as Chief Nutrition Officer.

Positive

Gelesis, Inc. Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available

2021-12-01 12:10:00

Gelesis, Inc. announced that Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults who meet the prescription criteria.

Neutral

Gelesis, Inc. Receives $30 Million Plenity Order from Ro

2021-11-18 12:10:00

Gelesis, Inc. announced that Ro has placed a $30 million fully paid pre-order for the company's first commercial product for weight management, Plenity®. Plenity was initially made available through a beta launch in 2020, and demand quickly outpaced supply while Gelesis worked to construct a larger manufacturing facility. Gelesis' first commercial-scale manufacturing line at the facility is now complete and validated. As Gelesis' exclusive telehealth partner in the U.S., Ro provides patients with access to telehealth options for weight management including the ability to communicate with a healthcare provider and, if safe and appropriate, to receive a prescription for Plenity through myplenity.com and Ro's digital clinics. The telehealth experience complements in-person healthcare provider care (available through any provider and powered by GoGoMeds), making it easier for people to seek treatment on their own time and their own terms.

Negative

Gelesis, Inc. Auditor Raises 'Going Concern' Doubt

2021-11-09 00:00:00

Gelesis, Inc. filed its Annual on Nov 09, 2021 for the period ending Dec 31, 2020. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Positive

Capstar Special Purpose Acquisition Corp., Gelesis, Inc. - M&A Call

2021-07-19 11:00:00

To discuss business combination agreement between Gelesis, Inc. and Capstar Special Purpose Acquisition Corp.

Positive

Gelesis, Inc. announced that it expects to receive $100 million in funding from Pacific Investment Management Company LLC, Pritzker/Vlock Family Office, Kennedy Lewis Investment Management LLC, China Medical System Holdings Limited, PureTech Health plc

2021-07-19 00:00:00

Gelesis, Inc. announced that it has entered into subscription agreements with certain investors for private placement of up to 10,000,000 class A shares at a price of $10 per share for gross proceeds of up to $100,000,000 on July 19, 2021. The transaction included participation from new and existing top tier investors and partners including private funds of Pacific Investment Management Company LLC, Pritzker/Vlock Family Office, Kennedy Lewis Investment Management LLC, China Medical System Holdings Limited, PureTech Health plc, and affiliates of the sponsor. Kennedy Lewis Investment Management LLC will invest $10,000,000 conditioned upon the closing of its $100,000,000 senior secured credit facility, which is subject to the completion of due diligence, final documentation, and customary closing conditions. Affiliates of the Sponsor will invest $35,000,000 in the transaction. The investors will acquire 7% stake in the company at a implied market value of $1,328,000,000. The transaction has been approved by the board of directors of the company. The transaction is expected to close in the fourth quarter of 2021, subject to the satisfaction of certain closing conditions. The company will issue securities pursuant to exemption provided under Section 4(a)(2) of the Securities Act.

Positive

Gelesis, Inc. entered letter of intent to acquire Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders for approximately $980 million in a reverse merger transaction.

2021-07-19 00:00:00

Gelesis, Inc. entered letter of intent to acquire Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders for $1.1 billion in a reverse merger transaction on April 15, 2021. Gelesis, Inc. entered into an agreement to acquire Capstar Special Purpose Acquisition Corp. from a group of shareholders on July 19, 2021. A maximum of approximately 109 million shares may be issued to holders of shares of Gelesis common stock, Gelesis options and Gelesis warrants in connection with the business combination. The transaction will provide up to $376 million in gross proceeds to the combined company from a combination of a $100 million common stock PIPE financing at $10.00 per share along with $276 million of cash held in Capstar’s trust account. The business combination agreement may be terminated by either CPSR or Gelesis if the closing has not occurred by January 18, 2022, subject to certain exceptions. On November 8, 2021, the parties entered into an amendment to the original business combination agreement which, among other things (i) adjusts the equity valuation of Gelesis from $900 million to $675 million (ii) increases the number of Earn Out shares available to be issued to Gelesis stockholders from 15 million to 23.5 million, (iii) provides for the issuance of 1.98 million additional Capstar Class A Shares to Gelesis stockholders, equal to the number of Capstar Class B Shares forfeited by the Sponsor and certain affiliates of the Sponsor in accordance with the Sponsor Letter Agreement Amendment and (iv) extends the termination date from January 18, 2022 to January 31, 2022. A maximum number of 96.03 million shares may now be issued to holders of shares of Gelesis common stock, options and warrants in connection with the business combination resulting in a total consideration of approximately $960 million. As of December 30, 2021, parties entered into second amendment which, among other things, removed the provisions relating to the issuance of 1,983,750 additional Capstar Class A Shares to Gelesis stockholders, equal to the number of Capstar Class B Shares forfeited by Capstar Sponsor Group LLC and certain affiliates of the Sponsor in accordance with the Amendment to Sponsor Letter Agreement entered into by Capstar and Gelesis on November 8, 2021. Upon completion, assuming no redemption, the Gelesis stockholders, will own 64.1%, PIPE investors will own 7.8%, CPSR public stockholders will own approximately 23.9% of the combined company. Upon completion of the transaction, the combined company’s securities are expected to be traded on the New York Stock Exchange (NYSE) under the symbol “GLS.” Following the consummation of the Business Combination, it is expected that the New Gelesis Board will consist of nine (9) directors, which will be divided into three classes (Class I, II and III) with each of Class I, II and III consisting of three directors. Capstar Board shall consist of a defined number of directors, among others. The transaction is subject to the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder relating to the Business Combination having been expired or been terminated and any other required regulatory approvals applicable to the transactions contemplated by the Business Combination Agreement having been obtained, registration statement being declared effective by the U.S. Securities and Exchange Commission, approval of CPSR and Gelesis shareholders, CPSR’s initial listing application with the New York Stock Exchange in connection with the transactions contemplated by the Business Combination Agreement having been approved, registration Statement / Proxy Statement shall have become effective and Capstar shall have at least $5,000,001 of net tangible assets. The transaction has been unanimously approved by the Boards of Directors of both Gelesis and CPSR. CPSR Board recommends that stockholders vote for the adoption of the agreement. On December 12, 2021, Jamie Weinstein resigned from position as a member of the board of directors, as he no longer supported the business combination. The transaction is expected to close in the fourth quarter of 2021. Citigroup Inc. (NYSE:C) acted as exclusive financial advisor and James T. Barrett and Eric J. Carlson of Goodwin Procter LLP acted as legal counsels to Gelesis. John Delgado and Robin Tang of UBS acted as financial advisor and Ernest Wechsler, Christopher Auguste, Adi Herman, Ilya Kontorovich, Jackson D. Mann, Alan R. Friedman, Harry Rubin, Irena Royzman, Marcus A. Colucci, Marissa J. Holob, Avram J. Cahn, Robert N. Holtzman, Kelly Schreiber, Barry Herzog, Helayne Oberman Stoopack and Charles S. Warren of Kramer Levin Naftalis & Frankel LLP acted as legal advisors to Capstar. BTIG, LLC also acted as financial advisor to Capstar. Michael J. Blankenship of Winston & Strawn represented the placement agents, Citigroup Global Markets Inc. and UBS Investment Bank. Mark Zimkind of Continental Stock Transfer & Trust Company acted as transfer agent to Capstar. MacKenzie Partners, Inc. acted as proxy solicitor to Capstar for a fee of $17,500, plus disbursements for such services. Marcum LLP provided independent auditor’s report on financials of Capstar while KPMG LLP provided independent auditor’s report on financials of Gelesis.

Fundamental Summary

Looking at Gelesis's financials of Q1 reflected decent results. Its income and value factors appear positive and give support for optimism regarding the likelihood of continued positive performance. Bottom line, Gelesis's financials indicate solid performance in terms of income and value, which leads us to believe that they may become interesting again in the next few months. But for right now, we gave the company an overall grade of 66 and a HOLD recommendation.

Gelesis reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 7.51 million compared to USD 3.1 million a year ago. Net loss was USD 5.7 million compared to USD 18.59 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 9.38 a year ago.

Business Description

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Sector Overview

Gelesis is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Gelesis's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 152.9 3.1% 76
Liabilities 131.1 -3.9% 47
Price to Book 14.1 23457.0% 98
Cash & Equivalents 34.0 6.1% 76
Equity 10.0 102.8% 48
EBITDA -106.3 -37.3% 46
Total Revenues 15.6 48.7% 41
Parameter Value Change Score
Return on Equity -187.8 95.3% 56
Net Cashflow -25.9 5.6% 64
Capital Expenditure -15.5 42.5% 92
Asset Turnover 0.1 163.4% 98
Free Cashflow -5.9 77.6% 90

* All values are TTM

The below chart reflects Gelesis's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Gelesis's peer average final assessment score stands on 66.0, Gelesis's score is 66.

  •  GLS
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 0 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 1 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 2 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 3 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 5 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 6 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 7 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 9 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 10 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 11 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 12 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 13 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 14 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 15 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 16 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 18 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 19 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 20 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 21 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 22 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 23 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 25 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 26 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 27 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 28 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 29 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 30 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 31 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 33 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 34 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 36 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 37 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 38 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 39 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 40 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 41 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 42 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 43 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 44 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 45 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 46 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 47 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 48 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 49 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 50 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 51 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 52 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 53 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 54 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 55 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 57 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 58 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 59 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 61 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 62 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 63 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 64 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 65 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 66 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 67 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 68 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 69 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 70 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 71 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 72 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 73 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 74 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 75 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 76 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 77 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 78 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 79 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 80 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 81 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 82 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 84 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 85 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 86 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 87 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 88 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Gelesis's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Gelesis's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.

Bearish 42
Close Price 1.54
52W Low 1.54
52W High 9.99
5D MA 1.63
50D MA 4.0
200D MA 6.69
MACD -0.8
RSI 4.27
STOCH 0.0

Balance Sheet Analysis

Overall, Gelesis's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Gelesis publishes impressive results related to book value factors in this report. Specifically, price to book ratio (P/B) now sits at 14.1 and represents a 23457.0% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. Therefore, its book value factors earned a score of 98. Also, Gelesis assets on their balance sheet, moved to 152.9, which is a 3.1% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 76. However, one concerning metric, Liabilities, stood out. At filing, Gelesis's liabilities were 131.1, representing a -3.9% change from the previous period. These liabilities metrics show that management has been unsuccessful in encouraging healthy growth while managing liabilities. Therefore, we rated their liabilities movement with a score of 47. Therefore, the company's balance sheet earned a grade of 78.

Parameter Value Change Score
Assets 152.9 3.1% 76
Liabilities 131.1 -3.9% 47
Price to Book 14.1 23457.0% 98
Cash & Equivalents 34.0 6.1% 76
Equity 10.0 102.8% 48
* All values are TTM

The below chart describes Gelesis's performance as reflected on its balance sheet with respect to its peers. While Gelesis received a balance sheet score of 78, the average of its peers stands on 78.0.

  •  GLS
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 0 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 1 1
Amgen Inc. 130.1B 72 68 86 53 62 69 2 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 3 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 5 1
BioNTech SE 34.0B 75 69 64 97 73 75 6 1
Seagen Inc. 32.9B 59 68 55 43 66 61 7 1
Biogen Inc. 29.7B 57 72 92 50 76 76 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 9 1
Incyte Corporation 16.8B 71 72 95 82 79 83 10 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 11 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 12 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 13 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 14 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 15 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 16 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 17 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 18 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 19 1
Alkermes plc 5.0B 63 66 46 54 71 62 20 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 21 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 22 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 23 1
Natera, Inc. 3.6B 73 65 43 95 42 54 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 25 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 26 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 27 1
CureVac N.V. 2.6B 49 64 75 52 52 57 28 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 29 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 30 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 31 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 33 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 34 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 36 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 37 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 38 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 39 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 40 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 41 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 42 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 43 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 44 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 45 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 46 1
CareDx, Inc 1.2B 54 67 52 39 51 52 47 1
Vericel Corporation 1.1B 51 65 56 53 61 57 48 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 49 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 50 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 51 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 52 1
MannKind Corporation 957.2M 79 59 50 40 64 57 53 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 54 1
Merus N.V. 941.6M 59 68 50 83 81 70 55 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 57 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 58 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 59 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 61 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 62 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 63 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 64 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 65 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 66 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 67 1
Geron Corporation 566.2M 69 72 37 59 62 60 68 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 69 1
Immatics N.V. 538.7M 56 70 84 95 73 76 70 1
Agenus Inc. 520.5M 73 62 37 55 60 54 71 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 72 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 73 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 74 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 75 1
Affimed N.V. 415.0M 56 66 63 56 47 54 76 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 77 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 78 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 79 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 80 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 81 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 82 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 84 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 85 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 86 1
AC Immune SA 299.8M 84 64 47 53 75 68 87 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 88 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Gelesis's income statement report highlighted several concerning metrics. Gelesis's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 41. Also, Gelesis's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -106.3, which represents a -37.3% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Therefore, their EBITDA component earned a score of 46. However, we can draw some encouragement from Gelesis's momentum in cash_flow generation. Return factors metrics and ratios were exceptional in this report. Gelesis reported a return on equity (ROE) ratio of -187.8, representing a change of 95.3% from the last report. Its return factor metrics are even more remarkable when compared to their peers. Therefore, its return factors component earned a score of 56. The companie's income statement, therefore, earned a score of 39.

Parameter Value Change Score
EBITDA -106.3 -37.3% 46
Total Revenues 15.6 48.7% 41
Return on Equity -187.8 95.3% 56
* All values are TTM

The below chart describes Gelesis's performance as reflected on its income statement with respect to its peers. While Gelesis received a income statement score of 39 , the average of its peers stands on 39.0.

  •  GLS
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 91 51 77 66 0 1
Zymeworks Inc. 324.7M 58 53 77 56 1 1
Amgen Inc. 130.1B 74 75 64 78 2 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 3 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 5 1
BioNTech SE 34.0B 41 89 75 79 6 1
Seagen Inc. 32.9B 54 65 70 62 7 1
Biogen Inc. 29.7B 90 57 73 70 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 9 1
Incyte Corporation 16.8B 59 77 60 73 10 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 11 1
United Therapeutics Corporation 10.6B 57 91 54 82 12 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 13 1
Exact Sciences Corporation 7.2B 57 67 54 62 14 1
Exelixis, Inc. 6.7B 54 91 54 81 15 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 16 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 18 1
Ascendis Pharma A/S 5.2B 38 68 46 54 19 1
Alkermes plc 5.0B 69 55 81 62 20 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 21 1
Novavax, Inc. 4.0B 41 89 54 75 22 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 23 1
Natera, Inc. 3.6B 52 51 78 52 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 25 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 26 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 27 1
CureVac N.V. 2.6B 45 83 71 74 28 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 29 1
Insmed Incorporated 2.4B 51 58 73 57 30 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 31 1
Abgenix Inc. 2.1B 47 47 47 47 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 33 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 34 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 36 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 37 1
Xencor, Inc. 1.6B 42 94 52 79 38 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 39 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 40 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 41 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 42 1
Veracyte, Inc. 1.4B 45 63 57 55 43 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 44 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 45 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 46 1
CareDx, Inc 1.2B 61 44 82 50 47 1
Vericel Corporation 1.1B 76 44 82 56 48 1
IVERIC bio, Inc. 1.1B 84 58 79 70 49 1
FibroGen, Inc. 1.0B 48 74 63 67 50 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 51 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 52 1
MannKind Corporation 957.2M 95 48 56 61 53 1
ImmunoGen, Inc. 946.1M 40 73 71 64 54 1
Merus N.V. 941.6M 48 60 59 54 55 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 57 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 58 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 59 1
Amarin Corporation plc 734.5M 95 44 82 63 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 61 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 62 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 63 1
CTI BioPharma Corp. 603.6M 84 50 62 59 64 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 65 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 66 1
AnaptysBio, Inc. 586.3M 97 50 77 68 67 1
Geron Corporation 566.2M 89 67 73 78 68 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 69 1
Immatics N.V. 538.7M 37 93 53 77 70 1
Agenus Inc. 520.5M 57 83 45 74 71 1
Radius Health, Inc. 499.8M 94 71 68 82 72 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 73 1
Vaxart, Inc. 440.0M 99 51 72 68 74 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 75 1
Affimed N.V. 415.0M 95 49 75 66 76 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 77 1
MiMedx Group, Inc. 391.5M 87 43 83 59 78 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 79 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 80 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 81 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 82 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 84 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 85 1
Silence Therapeutics plc 313.4M 83 64 69 72 86 1
AC Immune SA 299.8M 83 61 65 70 87 1
Precigen, Inc. 299.1M 57 87 59 79 88 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Asset Turnover and Capex, are driving the positive outlook for Gelesis's financial strength. Gelesis is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.1, representing a 163.4% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Therefore, its asset turnover movement earned a score of 98. Also, Gelesis's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -15.5, which represents a 42.5% change from the last period. This performance is all the more impressive relative to their peers and competitors. Consequently, their CapEx movement received a grade of 92. However, one discouraging result, Net Cash Flow, stood out. Gelesis's net cash flow metrics were -25.9 according to their current filing, which represents a 5.6% change from the previous report. Gelesis's net cash flow metrics are especially disappointing relative to their peers. Consequently, their net cash flow movement received a grade of 64. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 80.

Parameter Value Change Score
Net Cashflow -25.9 5.6% 64
Capital Expenditure -15.5 42.5% 92
Asset Turnover 0.1 163.4% 98
Free Cashflow -5.9 77.6% 90
* All values are TTM

The below chart describes Gelesis's performance as reflected on its cash flow with respect to its peers. While Gelesis received a cash flow score of 80, the average of its peers stands on 80.0.

  •  GLS
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 0 1
Zymeworks Inc. 324.7M 52 65 45 83 57 1 1
Amgen Inc. 130.1B 80 74 67 74 81 2 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 3 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 5 1
BioNTech SE 34.0B 73 97 50 52 72 6 1
Seagen Inc. 32.9B 53 53 50 87 58 7 1
Biogen Inc. 29.7B 58 54 90 73 66 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 9 1
Incyte Corporation 16.8B 78 79 92 74 84 10 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 11 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 12 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 13 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 14 1
Exelixis, Inc. 6.7B 79 90 89 83 87 15 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 16 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 17 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 18 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 19 1
Alkermes plc 5.0B 89 95 76 80 92 20 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 21 1
Novavax, Inc. 4.0B 62 38 63 54 60 22 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 23 1
Natera, Inc. 3.6B 52 54 56 84 58 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 25 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 26 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 27 1
CureVac N.V. 2.6B 87 80 90 70 90 28 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 29 1
Insmed Incorporated 2.4B 79 80 61 89 82 30 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 31 1
Abgenix Inc. 2.1B 66 53 45 59 58 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 33 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 34 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 36 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 37 1
Xencor, Inc. 1.6B 96 95 70 95 98 38 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 39 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 40 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 41 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 42 1
Veracyte, Inc. 1.4B 90 95 46 46 82 43 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 44 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 45 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 46 1
CareDx, Inc 1.2B 98 84 40 50 86 47 1
Vericel Corporation 1.1B 64 46 59 73 65 48 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 49 1
FibroGen, Inc. 1.0B 86 74 48 87 84 50 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 51 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 52 1
MannKind Corporation 957.2M 77 56 43 37 66 53 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 54 1
Merus N.V. 941.6M 70 71 74 53 71 55 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 56 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 57 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 58 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 59 1
Amarin Corporation plc 734.5M 52 40 74 55 55 60 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 61 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 62 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 63 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 64 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 65 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 66 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 67 1
Geron Corporation 566.2M 78 68 49 81 77 68 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 69 1
Immatics N.V. 538.7M 82 95 56 99 86 70 1
Agenus Inc. 520.5M 57 43 52 77 58 71 1
Radius Health, Inc. 499.8M 64 40 37 56 57 72 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 73 1
Vaxart, Inc. 440.0M 72 56 53 38 65 74 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 75 1
Affimed N.V. 415.0M 72 57 95 43 74 76 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 77 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 78 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 79 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 80 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 81 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 82 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 83 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 84 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 85 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 86 1
AC Immune SA 299.8M 66 77 79 63 68 87 1
Precigen, Inc. 299.1M 82 75 37 85 74 88 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.